Regarding a Report Concerning Sumitomo Pharma
Filed with TSE · · 1 page · English
Watch Sumitomo Pharma Co.Ltd's latest callSumitomo Pharma (Tokyo:4506) Q1 2026 Earnings Call · Replay · Aug 4Read the transcript of Sumitomo Pharma (Tokyo:4506) Q1 2026 Earnings CallSumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura; the “Company”) has confirmed that a report concerning the Company and its group companies was published by Gotham City Research LLC on August 3, 2026. The report reflects the independent views and assertions of its author and was not issued by the Company. The Company prepares and disclos
Sumitomo Pharma Co.Ltd. on 6ix
In the deck
Earlier from Sumitomo Pharma Co.Ltd
- Presentation Material (Conference on Q1 FY2026 Financial Results)
- Matters Concerning Controlling Shareholders, Etc.
- Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026
- Sumitomo Pharma Announces Organizational Change, Change in the Responsibilities of Executive Officer, and Personnel Change
- New Data from Sumitomo Pharma America at AUA 2026 Highlight Efficacy of Vibegron in Men Aged 75 and Older with Overactive Bladder and BPH
Later from Sumitomo Pharma Co.Ltd
- Additional Explanation Regarding the Report “Sumitomo Chemical and Sumitomo Pharmaceutical: The 116 billion yen Swiss Shuffle”
- Regarding a Report Concerning Sumitomo Pharma (The Company's Views on the GCR August 7 Report)
- Notice Concerning Gain on Return of Retirement Benefit Trust (Extraordinary Income) Recorded in the Company’s Non-Consolidated Financial Statements
- Presentation Material (Conference on Q2 FY2026 Financial Results
- Sumitomo Pharma Announces Revision of Its Year-End Dividend Forecast for the Fiscal Year Ending March 31, 2027
Follow Sumitomo Pharma Co.Ltd into a list and get an email when it puts out news.
Follow Sumitomo Pharma Co.Ltd